Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17.
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
Morgan Stanley analyst Patrick Wood maintains $RxSight(RXST.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 51.4% and a
RxSight (RXST) Gets a Buy From Morgan Stanley
RxSight Price Target Raised to $73.00/Share From $72.00 by BTIG
RxSight Price Target Raised to $73.00/Share From $72.00 by
RxSight Is Maintained at Buy by BTIG
RxSight Is Maintained at Buy by
BTIG Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $73
BTIG analyst Ryan Zimmerman maintains $RxSight(RXST.US)$ with a buy rating, and adjusts the target price from $72 to $73.According to TipRanks data, the analyst has a success rate of 46.6% and a
Express News | Rxsight Inc : Btig Raises Target Price to $73 From $72
Institutional Investors May Overlook RxSight, Inc.'s (NASDAQ:RXST) Recent US$280m Market Cap Drop as Long-term Gains Remain Positive
Key Insights Institutions' substantial holdings in RxSight implies that they have significant influence over the company's share price 50% of the business is held by the top 16 shareholders
RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55
RxSight Down Over 17%, on Pace for Record Percent Decrease -- Data Talk
RxSight, Inc. ( RXST ) is currently at $47.05, down $9.94 or 17.44% --Would be lowest close since March 18, 2024, when it closed at $46.76 --Would be largest percent decrease on record (Based on
Oppenheimer's Best 'SMID-cap' Ideas for 2024
Express News | RxSight Shares Are Trading Lower After Stifel Maintained a Buy Rating on the Stock and Lowered Its Price Target From $75 to $70
Stifel Maintains Buy on RxSight, Lowers Price Target to $70
Stifel analyst Thomas Stephan maintains RxSight (NASDAQ:RXST) with a Buy and lowers the price target from $75 to $70.
RxSight Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 22.79% Stifel $75 → $70 Maintains Buy 05/07/2024 19.28% Wells Fargo $61 → $68 Maintains
Stifel Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $70
Stifel analyst Thomas Stephan maintains $RxSight(RXST.US)$ with a buy rating, and adjusts the target price from $68 to $70.According to TipRanks data, the analyst has a success rate of 73.3% and a
Express News | Rxsight Inc : Stifel Cuts Target Price to $70 From $75
RxSight(RXST.US) Officer Sells US$1.08 Million in Common Stock
$RxSight(RXST.US)$ Officer Thunen Shelley B sold 18,402 shares of common stock on Jul 1, 2024 at an average price of $58.6793 for a total value of $1.08 million.Source: Announcement What is statement
Form 144 | RxSight(RXST.US) Officer Proposes to Sell 586.06K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $RxSight(RXST.US)$ Officer SHELLEY B THUNEN intends to sell 10,000 shares of its common stock on Jul 1, with a total market value of approximately $586.06K. SHELLEY B
Form 144 | RxSight(RXST.US) Officer Proposes to Sell 493.07K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $RxSight(RXST.US)$ Officer Thunen Shelley B intends to sell 8,402 shares of its common stock on Jul 1, with a total market value of approximately $493.07K. Thunen Shel